Cerenome reports US$0.7M CNSide revenue with trial data due in 2027
The US$20M facility carries interest and royalties, with future funding conditional ahead of mid-2027 cancer trial readouts.
Adrian Kessler
First CNSide diagnostic revenue reached US$0.7 million as Cerenome, Inc. NASDAQCNSY reported third-quarter 2026 results on Friday, alongside a US$8.7 million net loss. The loss widened from US$4.4 million a year earlier.
Cash, equivalents and investments totalled US$4.9 million on Sept. 30, before US$3.8 million raised through an equity distribution agreement after quarter-end. Cerenome expects mid-2027 trial readouts, while further funding under its secured facility depends on conditions.
Cerenome is an oncology company based in Houston, combining cerebrospinal fluid diagnostics with experimental radiopharmaceutical treatments for central nervous system cancers.
Cerenome shares NASDAQCNSY closed at US$0.95 at 4:00 p.m. EST on Nov. 13. The results were released after regular trading, so that price predates the announcement.
The Facility Combines Interest, Royalties And Conversion Rights
The September financing offers up to US$20 million, with an initial tranche funded at closing and future tranches conditional. That initial funding preceded the reported quarter-end liquidity balance. The Sept. 10 financing filing set an initial US$3 million gross funding tranche.
The notes carry annual interest of 8 per cent and an original issue discount of 6 per cent. Each matures one year after issuance unless extended, and can convert into common shares.
The terms also provide first-priority security over substantially all Cerenome and CNSide assets, subject to exclusions. CNSide owes a quarterly royalty of 2.5 per cent of gross revenues received, subject to exclusions and a cap.
That quarterly cap equals 2.5 per cent of the unpaid note balance. The royalty obligation continues until the notes and associated amounts are paid and the notes terminated or cancelled.
"This facility is designed to be minimally dilutive to stockholders while supporting the next stage of commercial scale-up and development of CNSide, specifically growing sales and broadening the pipeline," chief financial officer Andrew Sims said.
In its Sept. 10 financing announcement, Cerenome forecast cash runway well into 2028 using the facility, other existing facilities, current cash and forecast CNSide sales and cash flow. That September forecast incorporates funding and commercial assumptions beyond the quarter-end liquidity balance. The November financial-results and outlook sections give no revised runway estimate.
Read more: Milestone Pharmaceuticals plans 30 per cent expense cut to extend cash runway
Diagnostic Collections Precede The Trial Readouts
For the quarter ended Sept. 30, cost of revenue was US$0.9 million, exceeding diagnostic sales. Cerenome said commercial payments began in October, while contracted payer agreements now represent approximately 190 million covered lives.
Cerenome expects Medicare reimbursement in the first half of 2027 and is separately pursuing a coverage determination from Novitas Solutions. The reimbursement timetable remains Cerenome's forecast.
Among listed diagnostics companies, Lucid Diagnostics Inc. NASDAQLUCD reported US$1.2 million in third-quarter revenue on Nov. 12. Lucid said Medicare payments for its EsoGuard esophageal DNA test began in October through claim-by-claim adjudication, independently of a pending local coverage determination.
Read more: Lucid Diagnostics reports US$1.2M revenue and US$18M quarter-end cash
The broader State Street SPDR S&P Biotech ETF NYSEARCAXBI was US$151.20 as of 8:00 p.m. EST on Nov. 12.
Enrolment in the Phase 2 ReSPECT-GBM study of recurrent glioblastoma finished in October. Cerenome plans an FDA end-of-Phase 2 meeting after the mid-2027 results and also expects mid-2027 topline data from its repeat-dose leptomeningeal metastases study.
Cerenome says commercial expansion will include a larger field sales team, broader testing and greater adoption by cancer centres. Its next scheduled update is its Nov. 16 results call at 8:30 a.m. EST, covering quarterly finances and business progress ahead of those clinical readouts.
